Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

Small-cell lung cancer (SCLC) transformation from EGFR mutant adenocarcinoma is a rare entity that is considered to be a new phenotype of SCLC. While transformation from adenocarcinoma (ADC) with EGFR exon 19 deletions and exon 21 L858R point mutations has been described, to our knowledge, no cases...

Full description

Bibliographic Details
Main Authors:	Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Current Oncology
Subjects:	transformed SCLC EGFR exon 18
Online Access:	https://www.mdpi.com/1718-7729/30/3/265

Similar Items

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
by: Pascal Wang, et al.
Published: (2022-07-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
by: Meihui Li, et al.
Published: (2022-08-01)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
by: Taishu Wang, et al.
Published: (2018-07-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
by: Lingfei Wang, et al.
Published: (2020-07-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
by: Timothée Olivier, et al.
Published: (2022-09-01)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
by: Vishal Shah, et al.
Published: (2023-03-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
by: Yue Zheng, et al.
Published: (2023-11-01)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
by: Arsela Prelaj, et al.
Published: (2022-06-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
by: Ikei S. Kobayashi, et al.
Published: (2021-12-01)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
by: Binyang Pan, et al.
Published: (2023-11-01)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
by: Waleed Kian, et al.
Published: (2022-09-01)

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
by: Siqi Xiang, et al.
Published: (2023-11-01)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01)

Establishing a molecular protocol for detection of EGFR mutations in patients with non-small cell lung cancer
by: Thi Minh Ly Nguyen, et al.
Published: (2018-12-01)

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
by: Xiuyue Man, et al.
Published: (2024-06-01)

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
by: Kazumi Nishino, MD, PhD, et al.
Published: (2024-02-01)

Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
by: Xue YANG, et al.
Published: (2022-05-01)

KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response
by: Denise Barcelos, et al.
Published: (2018-11-01)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
by: Chao Shi, et al.
Published: (2022-09-01)

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report
by: Jaemin Kim, BS, et al.
Published: (2023-12-01)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
by: Jiabao Hou, et al.
Published: (2022-04-01)

Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
by: Weirui Wu, et al.
Published: (2024-08-01)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
by: Santiago Viteri, et al.
Published: (2023-02-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Exon skipping-rich transcriptomes of animals reflect the significance of exon-shuffling in metazoan proteome evolution
by: Laszlo Patthy
Published: (2019-01-01)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
by: Sai-Hong Ignatius Ou, MD, et al.
Published: (2023-10-01)

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
by: Meng Hu, et al.
Published: (2024-05-01)

Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors
by: Zhiqin Lu, et al.
Published: (2024-01-01)

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study
by: Madhusmita Behera, PhD, et al.
Published: (2024-06-01)

Partial transformation from non-small cell lung cancer to small cell lung cancer: a case report and literatures review
by: Yicong Lu, et al.
Published: (2025-03-01)

Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
by: Ahmed Abdalhadi, et al.
Published: (2024-02-01)

Bioinformatics-based screening of key genes for transformation of tyrosine kinase inhibitor-resistant lung adenocarcinoma to small cell lung cancer
by: Ying Zhang, et al.
Published: (2023-07-01)